Moffitt Cancer Center shared a post on X:
“At the SGOMtg plenary session, Maria Rubinstein, MD from Memorial Sloan Kettering Cancer Center shares findings from DB-1305/BNT325 (a novel TROP-2 ADC) in patients with ovarian cancer and highlights encouraging efficacy with a manageable safety profile.
Conclusions:
- DB-1305/BNT325 showed encouraging durable antitumor activity with ORR of 41.4%, DCR of 82.8%, mDOR of 7.3 months, and mPFS of 7.4 months (overall population; N=58).
- In 3 mg/kg (n=30): ORR of 40.0%, DCR of 80.0%, mDOR of 7.3 months, and mPFS of 7.4 months.
- DB-1305/BNT325 was generally well tolerated: stomatitis was the most common TRAE; both overall and Grade 3 events increased with higher doses in patients with ovarian cancer and in the overall population.
- Data support further global clinical development.
- Available clinical efficacy, safety, PK, and E-R analyses support further evaluation of DB-1305/BNT325 at 3 mg/kg Q3W in patients with platinum-resistant ovarian cancer.
- Study is ongoing and will evaluate the combination with BNT327, an anti-PD-L1 x VEGF-A bispecific antibody, which has shown early efficacy in patients with ovarian cancer.
- DB-1305/BNT325 demonstrated encouraging durable efficacy and a manageable safety profile in patients with previously treated ovarian cancer.”
